150 related articles for article (PubMed ID: 17495956)
21. Skin delivery potency and antitumor activities of temozolomide ester prodrugs.
Suppasansatorn P; Wang G; Conway BR; Wang W; Wang Y
Cancer Lett; 2006 Nov; 244(1):42-52. PubMed ID: 16412562
[TBL] [Abstract][Full Text] [Related]
22. Nanoemulsion preparations of the anticancer drug dacarbazine significantly increase its efficacy in a xenograft mouse melanoma model.
Tagne JB; Kakumanu S; Nicolosi RJ
Mol Pharm; 2008; 5(6):1055-63. PubMed ID: 19434855
[TBL] [Abstract][Full Text] [Related]
23. Combination of dacarbazine and dimethylfumarate efficiently reduces melanoma lymph node metastasis.
Valero T; Steele S; Neumüller K; Bracher A; Niederleithner H; Pehamberger H; Petzelbauer P; Loewe R
J Invest Dermatol; 2010 Apr; 130(4):1087-94. PubMed ID: 19940857
[TBL] [Abstract][Full Text] [Related]
24. Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma.
Ueno T; Ko SH; Grubbs E; Pruitt SK; Friedman HS; Tyler DS
Am J Surg; 2004 Nov; 188(5):532-7. PubMed ID: 15546565
[TBL] [Abstract][Full Text] [Related]
25. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
Aghi M; Rabkin S; Martuza RL
J Natl Cancer Inst; 2006 Jan; 98(1):38-50. PubMed ID: 16391370
[TBL] [Abstract][Full Text] [Related]
26. Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
Punt CJ; Suciu S; Gore MA; Koller J; Kruit WH; Thomas J; Patel P; Lienard D; Eggermont AM; Keilholz U
Eur J Cancer; 2006 Nov; 42(17):2991-5. PubMed ID: 17023156
[TBL] [Abstract][Full Text] [Related]
27. Vitamin D and its low calcemic analogs modulate the anticancer properties of cisplatin and dacarbazine in the human melanoma A375 cell line.
Piotrowska A; Wierzbicka J; Rybarczyk A; Tuckey RC; Slominski AT; Żmijewski MA
Int J Oncol; 2019 Apr; 54(4):1481-1495. PubMed ID: 30968156
[TBL] [Abstract][Full Text] [Related]
28. Combining adenoviral oncolysis with temozolomide improves cell killing of melanoma cells.
Quirin C; Mainka A; Hesse A; Nettelbeck DM
Int J Cancer; 2007 Dec; 121(12):2801-7. PubMed ID: 17724714
[TBL] [Abstract][Full Text] [Related]
29. Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity.
Ding B; Wu X; Fan W; Wu Z; Gao J; Zhang W; Ma L; Xiang W; Zhu Q; Liu J; Ding X; Gao S
Int J Nanomedicine; 2011; 6():1991-2005. PubMed ID: 21976975
[TBL] [Abstract][Full Text] [Related]
30. Treatment of brain metastases of malignant melanoma with temozolomide.
Biasco G; Pantaleo MA; Casadei S
N Engl J Med; 2001 Aug; 345(8):621-2. PubMed ID: 11529230
[No Abstract] [Full Text] [Related]
31. 3,3',4,4',5,5'-hexahydroxystilbene impairs melanoma progression in a metastatic mouse model.
Paulitschke V; Schicher N; Szekeres T; Jäger W; Elbling L; Riemer AB; Scheiner O; Trimurtulu G; Venkateswarlu S; Mikula M; Swoboda A; Fiebiger E; Gerner C; Pehamberger H; Kunstfeld R
J Invest Dermatol; 2010 Jun; 130(6):1668-79. PubMed ID: 19956188
[TBL] [Abstract][Full Text] [Related]
32. Systemic treatments for advanced cutaneous melanoma.
Anderson CM; Buzaid AC; Legha SS
Oncology (Williston Park); 1995 Nov; 9(11):1149-58; discussion 1163-4, 1167-8. PubMed ID: 8703684
[TBL] [Abstract][Full Text] [Related]
33. Thalidomide enhances the anti-tumor activity of standard chemotherapy in a human melanoma xenotransplatation model.
Heere-Ress E; Boehm J; Thallinger C; Hoeller C; Wacheck V; Birner P; Wolff K; Pehamberger H; Jansen B
J Invest Dermatol; 2005 Aug; 125(2):201-6. PubMed ID: 16098027
[TBL] [Abstract][Full Text] [Related]
34. Computed determination of the in vitro optimal chemocombinations of sphaeropsidin A with chemotherapeutic agents to combat melanomas.
Ingels A; Dinhof C; Garg AD; Maddau L; Masi M; Evidente A; Berger W; Dejaegher B; Mathieu V
Cancer Chemother Pharmacol; 2017 May; 79(5):971-983. PubMed ID: 28389780
[TBL] [Abstract][Full Text] [Related]
35. Quality of life, at what cost?
Oubre DN
Cancer Invest; 2003; 21(6):965-6. PubMed ID: 14735700
[No Abstract] [Full Text] [Related]
36. Targeting X-linked inhibitor of apoptosis protein to increase the efficacy of endoplasmic reticulum stress-induced apoptosis for melanoma therapy.
Hiscutt EL; Hill DS; Martin S; Kerr R; Harbottle A; Birch-Machin M; Redfern CP; Fulda S; Armstrong JL; Lovat PE
J Invest Dermatol; 2010 Sep; 130(9):2250-8. PubMed ID: 20520630
[TBL] [Abstract][Full Text] [Related]
37. Temozolomide-induced desquamative skin rash in a patient with metastatic melanoma.
Pick AM; Neff WJ; Nystrom KK
Pharmacotherapy; 2008 Mar; 28(3):406-9. PubMed ID: 18294121
[TBL] [Abstract][Full Text] [Related]
38. Combination therapy with dacarbazine and statins improved the survival rate in mice with metastatic melanoma.
Tsubaki M; Takeda T; Obata N; Kawashima K; Tabata M; Imano M; Satou T; Nishida S
J Cell Physiol; 2019 Aug; 234(10):17975-17989. PubMed ID: 30834527
[TBL] [Abstract][Full Text] [Related]
39. Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study.
Guillot B; Khamari A; Cupissol D; Delaunay M; Bedane C; Dreno B; Picot MC; Dereure O
Melanoma Res; 2008 Apr; 18(2):141-6. PubMed ID: 18337651
[TBL] [Abstract][Full Text] [Related]
40. Association of MITF and other melanosome-related proteins with chemoresistance in melanoma tumors and cell lines.
Hertzman Johansson C; Azimi A; Frostvik Stolt M; Shojaee S; Wiberg H; Grafström E; Hansson J; Egyházi Brage S
Melanoma Res; 2013 Oct; 23(5):360-5. PubMed ID: 23921446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
